Company info:
Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration deals with companies namely AstraZeneca,...
NKTR is due for earnings on August 8th. The price from the opening bell on the 7th
pump nearly 100% to over $1.00 and then faded by a couple of cents.
The Price Momentum Oscillator and ZL MACD indicators tracked the high velocity
action into a high tight type bull falg which is often considered to be predictive
of another leg up of similar magnitude. I will be...
Based on 6 Wall Street analysts offering 12 month price targets for Nektar Therapeutics in the last 3 months. The average price target is $2.75 with a high forecast of $6.00 and a low forecast of $1.00. The average price target represents a 308.07% change from the last price of $0.67.
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma,...
Hey my friends, NEKTAR THERAPEUTICS is in a compression zone, second attempt desperate for sellers with a large volume. Great possibility to break this area to look for the highest to breakout the balance area.
Please LIKE & FOLLOW, thank you!
Nektar Therapeutics (NKTR, $22.82) was one of top quarterly gainers, jumping +40.26% to $22.82 per share. My A.I.dvisor analyzed 169 stocks in the Pharmaceuticals: Major Industry over the last three months, and discovered that 156 of them (92.52%) charted an Uptrend while 13 of them (7.48%) trended down.My A.I.dvisor found 426 similar cases when NKTR's price went...
Nektar and Bristol-Myers Squibb announced today the companies have agreed to a new joint development plan to advance bempegaldesleukin (bempeg) plus Opdivo (nivolumab) into multiple new registrational trials (source: Yahoo Finance).
The 19% jump is making Nektar trading around its fair value. Likely, profit-taking will take place in the next sessions. I'm...
This is a speculative one as counter trend.
Huge volume stepped in around $16 & $20
reuters data on November 28th shows short interest of 18% of the float, and 11 days to cover. The stock hi fresh highs since august and could pressure those short, extending the potential upside
stop below 20 and target 30.
In my previous idea dated 12/21/2018, "NKTR SHORT 1-Year, Historical supports show more downside.", I pegged a bottom support at $16. (I realize it dropped slightly below that last month).
On 12/26/2018, I updated the idea to give a range for 12/31/2019, "Bullish/Bearish Outlook Dec 30th, 2019", pegging a Bearish sentiment at ~$16.32 and Bullish sentiment at...
Nektar Therapeutics got a big upside surprise on its earnings report for both earnings and revenue. With earnings and revenue trending up, $21-22 is a fair price for the stock given analyst estimates from before the earnings report. There's resistance at 21.34, so we may initially get rejected from that level.
In the near-to-mid-term, however, the earnings beat...
Entry level $22.25 = Target price $28.00 = Stop loss $21.00
Trade the huge gap in the chart
Stock is well below its average analysts price target @$31 and overweight rating.
Short interest 19.87% fuel a recovery rally.
Company profile
Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug...
With all the opioid lawsuits against drug manufactors NKTR stands as a clear choice for massive future gains. Why? NKTR has made a non-addictive opioid pending FDA Approval. Everyday 130 people die from overdosing on some form of opioid which is why creating a safe, non-addictive opioid is a huge feat.
This stock is at an incredible value, and the risk v reward...
NKTR’s innovation outlook is trending down based on a current score of 60 out of 99, outperforming sector average. Insiders sentiment is negative. Over the past 4 quarters NKTR beat earnings estimates 4 times.
For more analysis and articles visit our website.
